The Pharma Data

OCTOBER 18, 2020

BOSTON–( BUSINESS WIRE )– AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. Mr. Crist brings more than twenty years of oncology sales experience in both launch-stage and late-stage companies, building commercial organizations and developing high performing sales force teams.

Sales 52

Sales Clinical Trials Clinical Trials Containment 52

pharmaphorum

FEBRUARY 2, 2022

billion settlement as well as royalties on sales of one of its top HIV products. Along with the one-off settlement, Gilead has agreed to pay ViiV a 3% royalty rate on Biktarvy sales and any other bictegravir-containing product in the US until 5 October 2027, when ViiV’s US patent on dolutegravir expires. Revenue fall.

Sales 72

Sales Production Drugs Licensing 72

pharmaphorum

JANUARY 29, 2023

The Legend Biotech-partnered CAR-T hasn’t yet reached sales levels that warrant being reported in J&J’s quarterly results – in part because of manufacturing problems – but J&J said in its first-quarter results update last week that it expects the threshold to be reached in the first quarter of this year.

Trials 64

Trials Sales Antibody Containment 64

The Pharma Data

DECEMBER 29, 2020

First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. futility analysis).

Antibody 52

Antibody Trials Production Clinical Trials 52

pharmaphorum

DECEMBER 4, 2020

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC). The Exon 20-mutated population is fairly large in its own right, as these mutations are the third most prevalent primary EGFR mutation.

FDA Approval 68

FDA Approval Sales Antibody Marketing 68

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

The Pharma Data

JULY 27, 2021

Acquisition Complements Amgen’s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer. billion in cash. Reese, M.D., executive vice president of Research and Development at Amgen.

Production 52

Production Antibody Sales Manufacturing 52

Pharmaceutical Technology

MAY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Antibody 130

Antibody DNA Genome Genomics 130

The Pharma Data

JANUARY 17, 2021

The treatment is based on the Grifols immunoglobulin Gamunex®-C, and contains anti-SARS-COV-2 polyclonal antibodies from plasma donors who have recovered from COVID-19. It could also help contain outbreaks in places where the vaccination hasn’t begun or is still underway. BARCELONA, Spain , Jan.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Containment 52

The Pharma Data

DECEMBER 2, 2020

c/o Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com. This press release contains forward-looking statements. Legal Notice Regarding Forward-Looking Statements.

Containment 52

Containment DNA Sales Antibody 52

Roots Analysis

JUNE 6, 2024

Roots Analysis added The autoinjectors market research report forecast period from 2024 to 2035. The autoinjectors market is highly fragmented, featuring the presence of both established companies as well as emerging start-ups. Key Initiatives in the Autoinjectors Market Domain A.

Medicine 40

Medicine Drug Delivery Manufacturing Marketing 40

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

DECEMBER 5, 2020

NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma. These allow for the creation of bispecific antibodies that closely resemble natural human antibodies with no linkers or artificial sequences.

Antibody 40

Antibody Production Trials Medicine 40

The Pharma Data

DECEMBER 8, 2020

Jefferies, Stifel, Guggenheim Securities and RBC Capital Markets are acting as joint book-running managers for the offering. Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. About IGM Biosciences, Inc.

Antibody 52

Antibody Engineer Containment Sales 52

The Pharma Data

APRIL 4, 2023

With eight marketed biosimilars Sandoz is offering the broadest biosimilar portfolio and is the leading biosimilars company in Europe with more than two decades of experience. It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development. Source link: [link]

Medicine 40

Medicine Generic Pharmaceutical FDA Approval Marketing 40

The Pharma Data

JANUARY 26, 2021

Securities and Exchange Commission (“ SEC “) in relation to up to US$250,000,000 in market value of its securities. capital markets. The Registration Statement also contains a preliminary prospectus supplement relating to an “at-the-market” sales agreement, which the Company expects to enter into with B. (the

Life Science 40

Life Science Sales Antibody Marketing 40

The Pharma Data

JANUARY 27, 2021

RIIB antibody BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) in patients with indolent relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). (Nasdaq: CASI), a U.S. Wei-Wu He , Ph.D., About BioInvent. The Company’s validated, proprietary F.I.R.S.T

Antibody 52

Antibody Containment Development Trials 52

The Pharma Data

DECEMBER 8, 2020

LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com ; or Citigroup Global Markets Inc., About Syndax Pharmaceuticals, Inc. Syndax’s Cautionary Note on Forward-Looking Statements .

Containment 52

Containment Sales Marketing Antibody 52

The Pharma Data

JANUARY 4, 2021

IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format. IPH6101/SAR443579 is a NKp46-based NK cell engager (NKCE) using Innate’s proprietary multispecific antibody format (Gauthier et al. MARSEILLE, France, Jan. MARSEILLE, France, Jan. Cell 2019 ).

Development 52

Development Antibody Drugs Containment 52

XTalks

MAY 1, 2023

Qalsody contains tofersen, an antisense oligonucleotide that specifically targets the mRNA made from mutated SODI genes to prevent the formation of toxic SOD1 proteins. At its peak sales, Qalsody is expected to generate around $300 million for Biogen. At its peak sales, Qalsody is expected to generate around $300 million for Biogen.

FDA Approval 89

FDA Approval Gene Genetics Protein 89

The Pharma Data

JUNE 17, 2022

With a strong portfolio of eight marketed biosimilars and a further 15+ in various stages of development, Sandoz has an unparalleled heritage and extensive expertise in the development, manufacturing and delivery of biosimilar medicines to patients and the healthcare community worldwide. Source link: [link].

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

Drug Discovery World

OCTOBER 20, 2022

Japan continues to be one of the largest pharmaceutical markets in the world, despite what the International Trade Administration described as ‘a challenging business landscape due to demographics’ 1. According to the International Trade Administration’s market overview, anti-tumour agents brought in the largest sales in 2020 in Japan.

Development 52

Development Drugs Life Science Marketing 52

The Pharma Data

DECEMBER 1, 2020

BeiGene will not receive any of the proceeds from the sale of the shares offered by the Selling Shareholders but will bear certain expenses incident to this offering (excluding underwriting discounts and commissions). We also market or plan to market in China additional oncology products licensed from Amgen Inc., About BeiGene.

Sales 40

Sales Marketing Production Development 40

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. million in the second quarter of 2021 for its COVID-19 antibodies. million of revenue associated with the sale of its rights to Cialis ® in China. on a non-GAAP basis.

Antibody 52

Antibody Sales Production Development 52

The Pharma Data

OCTOBER 15, 2020

Y-mAbs is a development-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. NEW YORK, Oct. 16, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics Inc. About Y-mAbs.

Production 52

Production Development Marketing Licensing 52

pharmaphorum

SEPTEMBER 18, 2020

German and Swiss pharma companies dominated the Swedish market at this time and it wasn’t until 1913 that the discussions were turned into a pharmaceutical company, Astra AB. Astra introduced two important product families onto the Swedish market in 1948: penicillin and anaesthetics, initially in the form of Xylocaine.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

pharmaphorum

AUGUST 16, 2020

The fund has already been deployed to order Gilead’s antiviral drug Veklury (remdesivir) and apheresis equipment to collect antibodies from the blood of patients who have recovered from COVID-19.

Vaccination 110

Vaccination Vaccine Immune Response Trials 110

The Pharma Data

DECEMBER 14, 2020

Attention: Equity Capital Markets, 55 East 52nd Street, 37th Floor, New York, NY 10055, by telephone at (888) 474-0200, or email: ecm.prospectus@evercore.com ; and Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., Attention: Capital Markets, 499 Park Ave., ABOUT TG THERAPEUTICS, INC.

Clinical Trials 40

Clinical Trials Clinical Trials Clinical Development Antibody 40

The Pharma Data

DECEMBER 28, 2020

Through its robust and citywide partnerships, The Corps helps New Yorkers receive free, safe and confidential testing for COVID-19 and for the antibody test. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information, visit [link].

Genetics 52

Genetics Sales Gene Sequencing Marketing 52

The Pharma Data

JANUARY 7, 2021

The Company also has granted to the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock at the Public Offering Price to cover over-allotments in the sales of the securities, if any. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. About Cerecor Inc.

Sales 52

Sales Clinical Development Development Containment 52

The Pharma Data

NOVEMBER 27, 2020

the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. About Y-mAbs.

FDA Approval 52

FDA Approval Production Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 5, 2020

net sales increased 11% to $1.32 Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07 “This is evidenced by Dupixent achieving in excess of $1 billion in global net sales this quarter.” REGN-COV2 , a dual antibody therapy to SARS-CoV-2 virus.

Sales 52

Sales Production Manufacturing Antibody 52

pharmaphorum

JANUARY 5, 2022

New oral therapies join the existing monoclonal antibody cocktails and include molnupiravir (Lagevrio, Merck) and a combination of the new antiviral nirmatrelvir with the HIV antiviral ritonavir (Paxlovid, Pfizer). Aduhelm’s Q3/2021 sales were $300k; investors will expect strong ramp-up in H1/2022. CNS’s moment of truth.

Vaccination 83

Vaccination Vaccine Antibody FDA Approval 83

The Pharma Data

SEPTEMBER 1, 2020

Basel, 1 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will launch a SARS-CoV-2 Rapid Antigen Test, in late September, for markets accepting the CE Mark. with whom Roche has a global distribution agreement and had also launched a Rapid Antibody Test in July. Food and Drug Administration (FDA).

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

The Pharma Data

MARCH 8, 2021

Canakinumab is a human monoclonal antibody that binds with high affinity and selectivity to human interleukin-1beta (IL-1?) This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. About canakinumab (ACZ885). 6 , 7 and neutralizes IL-1? Disclaimer.

Trials 52

Trials Immune Response Containment Clinical Trials 52

The Pharma Data

OCTOBER 30, 2020

NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc. Cohort 3: patients on mechanical ventilation.

Production 52

Production Antibody Manufacturing Trials 52

The Pharma Data

JANUARY 6, 2021

.” Based on the collaboration agreement, CureVac will be the Marketing Authorization Holder for the product, while Bayer will support CureVac with country operations within the European Union (EU) and selected additional markets. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros.

Vaccination 52

Vaccination Vaccine Development Production 52